NASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis $114.97 +16.78 (+17.09%) Closing price 04:00 PM EasternExtended Trading$112.54 -2.43 (-2.11%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Guardant Health Stock (NASDAQ:GH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Guardant Health alerts:Sign Up Key Stats Today's Range$100.48▼$115.0850-Day Range$78.60▼$99.9452-Week Range$36.36▼$120.74Volume4.47 million shsAverage Volume2.06 million shsMarket Capitalization$15.25 billionP/E RatioN/ADividend YieldN/APrice Target$129.42Consensus RatingModerate Buy Company Overview Guardant Health, Inc. is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide. The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes. Guardant360 CDx has received regulatory approval as a companion diagnostic for targeted therapies, while Guardant Reveal offers a blood-based solution for minimal residual disease (MRD) monitoring in early-stage colorectal cancer. Guardant Health is also developing its LUNAR platform for multi-cancer early detection through screening applications. Guardant Health operates CLIA-certified, CAP-accredited laboratories in the United States and has expanded service offerings across Europe and Asia through partnerships and regional laboratory certifications. The company collaborates with pharmaceutical and biotechnology firms on clinical trials to accelerate drug development and optimize patient selection for targeted therapies. Its commercial and research testing services support oncology practices, academic institutions and life science organizations globally. The company was co-founded by Helmy Eltoukhy, who serves as Chief Executive Officer, and AmirAli Talasaz, President and Co-founder. Under their leadership, Guardant Health has grown its product pipeline, secured regulatory clearances and forged strategic alliances to advance the use of liquid biopsy in precision oncology.AI Generated. May Contain Errors. Read More Guardant Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreGH MarketRank™: Guardant Health scored higher than 52% of companies evaluated by MarketBeat, and ranked 264th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGuardant Health has a consensus price target of $129.42, representing about 14.0% upside from its current price of $113.51.Amount of Analyst CoverageGuardant Health has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($2.87) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -33.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -33.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Guardant Health's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.23% of the float of Guardant Health has been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 6.12.Change versus previous monthShort interest in Guardant Health has recently increased by 10.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentGuardant Health has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Guardant Health this week, compared to 7 articles on an average week.Search Interest23 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 360% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,802,899.00 in company stock.Percentage Held by Insiders5.60% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GH Stock News HeadlinesGuardant wins FDA nod for Guardant360 Liquid CDx cancer test1 hour ago | seekingalpha.comGuardant Health leaps on a major win in cancer detection; will shares break out?1 hour ago | msn.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 116 Shares of StockMay 20 at 7:06 AM | insidertrades.comGuardant Health Touts Oncology, Shield Momentum Behind Guidance BoostMay 20 at 3:35 AM | americanbankingnews.comWhy Guardant Health (GH) Stock Is Down TodayMay 19 at 2:54 PM | finance.yahoo.comGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18 at 4:51 PM | businesswire.comInsider Selling: Guardant Health (NASDAQ:GH) CEO Sells 50,000 Shares of StockMay 14, 2026 | insidertrades.comSee More Headlines GH Stock Analysis - Frequently Asked Questions How have GH shares performed this year? Guardant Health's stock was trading at $102.14 at the start of the year. Since then, GH shares have increased by 11.1% and is now trading at $113.5090. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) posted its earnings results on Thursday, February, 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.07. Guardant Health's revenue was up 39.4% on a year-over-year basis. Read the conference call transcript. When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Top institutional investors of Guardant Health include The Manufacturers Life Insurance Company (0.91%), Temasek Holdings Private Ltd (0.74%), Emerald Advisers LLC (0.64%) and Allspring Global Investments Holdings LLC (0.46%). Insiders that own company stock include Amirali Talasaz, Helmy Eltoukhy, Michael Brian Bell, John G Saia, Chris Freeman, Terilyn J Monroe, Myrtle S Potter, Kumud Kalia, Meghan V Joyce, Ian T Clark, Musa Tariq, Darya Chudova and Medina Manuel Hidalgo. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Salesforce (CRM), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings2/19/2026Today5/20/202646th Annual William Blair Growth Stock Conference6/02/2026Jefferies Global Healthcare Conference 20266/03/2026AGM 20266/17/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, GH's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:GH CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees2,506Year Founded2012Price Target and Rating Average Price Target for Guardant Health$129.42 High Price Target$180.00 Low Price Target$60.00 Potential Upside/Downside+12.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$416.28 million Net Margins-40.10% Pretax Margin-40.21% Return on EquityN/A Return on Assets-26.42% Debt Debt-to-Equity RatioN/A Current Ratio4.68 Quick Ratio4.39 Sales & Book Value Annual Sales$1.08 billion Price / Sales14.11 Cash FlowN/A Price / Cash FlowN/A Book Value($1.37) per share Price / Book-83.92Miscellaneous Outstanding Shares132,600,000Free Float125,174,000Market Cap$15.25 billion OptionableNot Optionable Beta1.48 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GH) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardant Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
